RGS3 and breast cancer: discovered that CCT5, RGS3, and YKT6 mRNA expressions, which were upregulated in p53-mutated breast cancers, might be involved in resistance to docetaxel and clinically feasible in distinguish the subset of breast cancer patients who may or may not be benefit from docetaxel therapy (46).